<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470729</url>
  </required_header>
  <id_info>
    <org_study_id>P100125</org_study_id>
    <nct_id>NCT01470729</nct_id>
  </id_info>
  <brief_title>Biomarkers in Autosomal Dominant Cerebellar Ataxia</brief_title>
  <acronym>BIOSCA</acronym>
  <official_title>Identification of Biomarkers in Patients With Autosomal Dominant Cerebellar Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autosomal dominant cerebellar ataxias (ADCA) are a group of neurodegenerative disorders that&#xD;
      are clinically and genetically various. BIOSCA study aims to identify markers of the&#xD;
      metabolism (energy production inside the cells) in the blood and the brain of ADCA 1,2,3 and&#xD;
      7 patients and control subjects, in the perspective of future therapeutic trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rational. Autosomal dominant cerebellar ataxias (ADCA) are a clinically heterogeneous group&#xD;
      of neurodegenerative disorders caused by unstable CAG repeat expansions encoding&#xD;
      polyglutamine tracts. ADCA have a wide range of neurological symptoms including ataxia of&#xD;
      gait, stance, and limbs, cerebellar dysarthria, oculomotor disturbances of cerebellar and&#xD;
      supranuclear genesis, retinopathy, optic atrophy, spasticity, extra-pyramidal movement&#xD;
      disorders, peripheral neuropathy, sphincter disturbances, cognitive impairment, and epilepsy.&#xD;
      Corresponding to neuropathological findings in hereditary ataxia, there are three fundamental&#xD;
      patterns of degeneration on MRI: spinal atrophy, olivopontocerebellar atrophy, and cortical&#xD;
      cerebellar atrophy. We previously showed an hypercatabolism in premanifest and early stage&#xD;
      Huntington's disease (HD), along with a systemic metabolic defect: progressive decrease of&#xD;
      the plasmatic branched-chain amino acids (BCAA) - correlated with low serum IGF1&#xD;
      (insulin-like growth factor 1) - and muscle energy metabolism abnormalities measured by&#xD;
      31P-NMR spectroscopy. We also observed a weight loss in SCA1, 3 and mostly SCA7 patients. In&#xD;
      addition, we underlined in a preliminary study a significant decrease of the BCAA in SCA1,2,3&#xD;
      and 7 patients, suggesting that an energy deficit would also be implied in SCA pathogenesis.&#xD;
      Transcriptional interferences are likely a part of SCA physiopathology, as shown in the&#xD;
      retinal cells of a SCA7 mouse model, or as we detected over the cerebellum growth of these&#xD;
      mice. The hallmark of the gene expression studies in SCA1 and SCA7 mice points out the&#xD;
      implication of IGF1 pathway and IGF1 receptor. As in HD, these transcriptional disorders&#xD;
      might witness the metabolic defects above-mentioned.&#xD;
&#xD;
      Study objectives. The primary aim of the study is to provide metabolic and imaging biomarkers&#xD;
      in SCA1,2,3 and 7 patients and controls in the perspective of future therapeutic trials.&#xD;
&#xD;
      The secondary aims are to determine (i) an systemic energy profile in SCA1,2,3 and 7 patients&#xD;
      with the confirmation of an hypercatabolic status, (ii) a brain energy profile in SCA1,2,3&#xD;
      and 7 patients measured by in vivo 31P-NMR spectroscopy.&#xD;
&#xD;
      Study population. BIOSCA will recruit 120 participants in the Pitie Salpetriere University&#xD;
      Hospital located in Paris, France. The target cohort will be 80 patients - divided into 4&#xD;
      groups of 20 participants of each mutation - and 40 controls.&#xD;
&#xD;
      Study design. All patients (SCA1,2,3,7) will be assessed at baseline (visit 1), 1 year (visit&#xD;
      2) and 2 years (visit 3). At visit 1 and 3, subjects will undergo clinical, MRI, a bone&#xD;
      mineral density and a resting metabolic rate assessments, as well as donating fasted blood&#xD;
      samples. Each visit will last approximately 6 hours. At visit 2, they will have only a&#xD;
      clinical assessment along with a fasted blood sample. Control subjects will be seen only at&#xD;
      visit 1 and 3 with the same assessments as the patients.&#xD;
&#xD;
      Study period. BIOSCA is a prospective study for which each participant is enrolled for 24&#xD;
      months. The study duration is 36 months. The start date is November 2011.&#xD;
&#xD;
      Funding. BIOSCA is funded by a national funding hospital program in clinical research (PHRC)&#xD;
      from APHP institution.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>metabolic biomarkers of SCA</measure>
    <time_frame>12 months or 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>imaging biomarkers of SCA</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">102</enrollment>
  <condition>Spinocerebellar Ataxia Type 1</condition>
  <condition>Spinocerebellar Ataxia Type 2</condition>
  <condition>Spinocerebellar Ataxia, Autosomal Recessive 3</condition>
  <condition>Episodic Ataxia, Type 7</condition>
  <arm_group>
    <arm_group_label>Spinocerebellar Ataxia type 1 (SCA1)</arm_group_label>
    <description>Spinocerebellar Ataxia type 1 (SCA1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spinocerebellar Ataxia type 2 (SCA2)</arm_group_label>
    <description>Spinocerebellar Ataxia type 2 (SCA2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spinocerebellar Ataxia type 3 (SCA3)</arm_group_label>
    <description>Spinocerebellar Ataxia type 3 (SCA3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spinocerebellar Ataxia type 7 (SCA7)</arm_group_label>
    <description>Spinocerebellar Ataxia type 7 (SCA7)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>metabolic and imaging biomarkers in SCA1,2,3 and 7 patients</intervention_name>
    <description>MRI, a bone mineral density and a resting metabolic rate assessments, as well as donating fasted blood samples</description>
    <arm_group_label>Spinocerebellar Ataxia type 1 (SCA1)</arm_group_label>
    <arm_group_label>Spinocerebellar Ataxia type 2 (SCA2)</arm_group_label>
    <arm_group_label>Spinocerebellar Ataxia type 3 (SCA3)</arm_group_label>
    <arm_group_label>Spinocerebellar Ataxia type 7 (SCA7)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Spinocerebellar Ataxia Type 1 (SCA1) Spinocerebellar Ataxia Type 2 (SCA2) Spinocerebellar&#xD;
        Ataxia Type 3 (SCA3) Spinocerebellar Ataxia Type 7 (SCA7)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  More than 18 years of age&#xD;
&#xD;
          -  Ability to tolerate MRI&#xD;
&#xD;
          -  Positive genetic test to SCA1, 2, 3 or 7&#xD;
&#xD;
          -  Coverage by social insurance&#xD;
&#xD;
          -  Written informed consent must be obtained from the subject&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Less than 18 years of age&#xD;
&#xD;
          -  Concomitant significant neurological disorder&#xD;
&#xD;
          -  Unsuitability for MRI, e.g. claustrophobia, metal implants&#xD;
&#xD;
          -  History of significant head injury&#xD;
&#xD;
          -  Unability to receive an informed explanation about the protocol&#xD;
&#xD;
          -  Unability to complete the protocol&#xD;
&#xD;
          -  Non coverage by social insurance&#xD;
&#xD;
          -  No written informed consent obtained&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra DURR, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Adanyeguh IM, Henry PG, Nguyen TM, Rinaldi D, Jauffret C, Valabregue R, Emir UE, Deelchand DK, Brice A, Eberly LE, Öz G, Durr A, Mochel F. In vivo neurometabolic profiling in patients with spinocerebellar ataxia types 1, 2, 3, and 7. Mov Disord. 2015 Apr 15;30(5):662-70. doi: 10.1002/mds.26181. Epub 2015 Mar 15.</citation>
    <PMID>25773989</PMID>
  </results_reference>
  <results_reference>
    <citation>Adanyeguh IM, Perlbarg V, Henry PG, Rinaldi D, Petit E, Valabregue R, Brice A, Durr A, Mochel F. Autosomal dominant cerebellar ataxias: Imaging biomarkers with high effect sizes. Neuroimage Clin. 2018 Jun 14;19:858-867. doi: 10.1016/j.nicl.2018.06.011. eCollection 2018.</citation>
    <PMID>29922574</PMID>
  </results_reference>
  <results_reference>
    <citation>Garali I, Adanyeguh IM, Ichou F, Perlbarg V, Seyer A, Colsch B, Moszer I, Guillemot V, Durr A, Mochel F, Tenenhaus A. A strategy for multimodal data integration: application to biomarkers identification in spinocerebellar ataxia. Brief Bioinform. 2018 Nov 27;19(6):1356-1369. doi: 10.1093/bib/bbx060.</citation>
    <PMID>29106465</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>November 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinocerebellar ataxia, energy metabolism, NMR spectroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Spinocerebellar Ataxias</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

